DailyEdge

US stock futures were muted on Tuesday as crosscurrents from bank earnings, a chip sell-off, and volatile oil prices clouded the market outlook.

Buckle your seatbelts and keep all hands and feet inside the vehicle, because earnings season is back.

Humana Inc. (NYSE: HUM), a leading consumer healthcare company focused on helping people achieve their best health, announced improved Star Ratings for 2027, with 95% of its Medicare Advantage members enrolled in plans rated 4 stars or higher by the Centers for Medicare & Medicaid Services (CMS). Additionally, 42% of Humana's Medicare Advantage members are enrolled in 4.5-star plans for 2027.

Chipmaker Wolfspeed (WOLF) said on Wednesday that it received a conditional loan commitment of up to $1.5 billion from the US Department of Defense to expand domestic production of silicon carbide materials and power devices, sending its shares up 27% in extended trading.

US stock futures fell on Wednesday morning as global bonds declined and investors awaited minutes from the Fed's September meeting.

Drug distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice are nearing a deal to acquire infusion services provider Option Care Health in a transaction valued at more than $5 billion, including debt, the Financial Times reported on Monday, citing people familiar with the matter.

France’s Schneider Electric is nearing a deal to buy US software group PTC for about $20 billion, the Financial Times reported on Sunday, citing people with knowledge of the matter.

Broadcom Inc.’s Wall Street syndicate is preparing to raise $60 billion in fresh AI chip financing to support Anthropic PBC and other companies, according to people familiar with the matter.

Shares of biotechnology company United Therapeutics (NASDAQ: UTHR) jumped 13.6% in the afternoon session after a federal district court ruled that competitor Liquidia Corporation infringed patent claims covering United Therapeutics' inhaled treprostinil treatments.

Iovance Biotherapeutics (NASDAQ: IOVA) saw its share price increase by 31.48 percent on Tuesday, finishing at $14.45 per share after raising its full-year revenue growth guidance by as much as 60 percent, driven by strong demand for its cancer treatments.